Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLPH-211
- Development stage
- Unknown
- Lead developer
- Cellphire Therapeutics
- Modality
- Cell Therapies
- Administration
- Topical
01
Overview
CLPH-211 is an investigational, freeze-dried platelet-derived hemostatic agent being developed by Cellphire Therapeutics. It is part of the company's Freeze-Dried Platelet-Derived Hemostat Platform and is intended for use in operating room hemostasis to control bleeding. The product aims to provide a consistent, off-the-shelf alternative to autologous platelet-rich plasma (PRP), addressing variability and composition issues associated with single-donor PRP products. As of 2025, CLPH-211 is in Phase 2 clinical trials in Denmark[1][2]. Its mechanism leverages the aggregation function of platelets to promote blood coagulation at sites of bleeding.
Beyond the preview
Go deeper on CLPH-211.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLPH-211.